HUMA
HUMA
NASDAQ · Biotechnology

Humacyte Inc

$0.68
-0.10 (-13.21%)
As of Mar 29, 10:36 PM ET ·
Financial Highlights (FY 2025)
Revenue
173.28M
Net Income
5.24M
Gross Margin
41.4%
Profit Margin
3.0%
Rev Growth
+9.0%
D/E Ratio
0.62
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 41.4% 41.4% 41.4%
Operating Margin 4.6% 4.5% 4.7%
Profit Margin 3.0% 3.2% 3.4%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 173.28M 180.17M 139.91M
Gross Profit 71.75M 74.60M 57.93M
Operating Income 8.04M 8.07M 6.54M
Net Income 5.24M 5.71M 4.80M
Gross Margin 41.4% 41.4% 41.4%
Operating Margin 4.6% 4.5% 4.7%
Profit Margin 3.0% 3.2% 3.4%
Rev Growth +9.0% +21.8% +16.2%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 81.63M 75.78M 80.20M
Total Equity 132.28M 156.42M 129.75M
D/E Ratio 0.62 0.48 0.62
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 9.18M 9.37M 7.10M
Free Cash Flow 6.14M 5.00M 3.87M